SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
EVOK (MC $22 M) CHEAPEST FDA play-Drug targeting $3+ BILLION
An SI Board Since November 2019
Posts SubjectMarks Bans Symbol
4 1 0 EVOK
Emcee:  BioHero Type:  Moderated
CHEAPEST FDA Play with MASSIVE upside potential .stock is still under radar but this will change once they resubmit the NDA in this Quarter .

MEGA Drug targeting a $3+ BILLION Market is close to NDA-Resubmission expected before year end with potential FDA approval in Q2 .Market cap of $22 million is a PURE GIFT , this low float stock could run to $4+ even BEFORE FDA Decision . Now is the perfect time to load up before the news about NDA resubmission hit the wire which likely will attract more new investors .GL


Evoke Pharma (EVOK)

Market-Cap: $22 Million
Cash: $6.5 Million (additional ~$5 million available via ATM)
Price: $0.90

Shares Out: 24.1 Million


Presentation
evokepharmainc.gcs-web.com


•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women

•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options

•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually

•Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence

•Estimated $3-4B prescription market

•Resubmission of 505(b)(2) NDA expected Q4 2019

If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.




Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
globenewswire.com


Größten Aktionäre

Latterell ...2.1M
Michigan ...400.0K
Garner (Cam L) ...335.6K
Gonyer (David A) ...319.5K
D’Onofrio ...238.8K
The Vanguard ...224.8K
Geode Capital ...107.4K
Creative ...100.0K
Virtu Americas LLC ...70.3K
Citadel LLC ...59.0K
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):